미세 침 흡인 생검 세포학으로 갑상선의 포르말린 고정한 파라핀포매 블록의 BRAF V600E 돌연변이 분석
BRAFV600E Mutation Analysis in Fine Needle Aspiration Biopsy Cytology and Formalin Fixed Paraffin Embedding Block of the Thyroid
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Fine Needle Aspiration Biopsy Cytology (FNABC), which is known as the most accurate and cost-effective method for diagnosis of the thyroid nodule, may still result in indeterminate cases that are cellular paucity and show minor nuclear atypia. However, most cases are associated with suspicion of papillary thyroid carcinoma (PTC). A B-type Raf kinase (BRAF ) mutation was found in about half of PTCs which is currently helping us to differentiate malignancies from benign lesions. Cases studied included 46 histological, confirmed PTC cases. FNABC 102 cell paucity and 74 atypia benign cases were previously diagnosed as suspicious of PTC using cytologic examination. These cases were analyzed for BRAF mutation by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) with a new restriction enzyme. In this study, the sensitivity and specificity were calculated and, BRAF mutation was detected by means of a histological method in 23 of 46 cases of PTC and no mutation was found in 22 cases. However, one case was not detected. In using FNABC, BRAF mutation was detected in 6 of 102 cases in cell paucity and in 11 of 74 cases in the atypia. Two cases were not detected in the atypia. The sensitivity and specificity of PCR-RFLP in FNABC were 60% and 97.4% respectively. Assessment of Formalin Fixed Paraffin Embedding (FFPE) block demonstrated similarly a 51.1% positive and 48.9% negative in PTC. Evaluation of BRAF mutation revealed high specificity and low sensitivity in using FNABC method. This study suggests that BRAF mutation analysis should be useful for the clinical diagnosis of PTC in FNABC with cytological findings suspicious for PTC.
Abstract
Fine Needle Aspiration Biopsy Cytology (FNABC), which is known as the most accurate and cost-effective method for diagnosis of the thyroid nodule, may still result in indeterminate cases that are cellular paucity and show minor nuclear atypia. However, most cases are associated with suspicion of papillary thyroid carcinoma (PTC). A B-type Raf kinase (BRAF ) mutation was found in about half of PTCs which is currently helping us to differentiate malignancies from benign lesions. Cases studied included 46 histological, confirmed PTC cases. FNABC 102 cell paucity and 74 atypia benign cases were previously diagnosed as suspicious of PTC using cytologic examination. These cases were analyzed for BRAF mutation by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) with a new restriction enzyme. In this study, the sensitivity and specificity were calculated and, BRAF mutation was detected by means of a histological method in 23 of 46 cases of PTC and no mutation was found in 22 cases. However, one case was not detected. In using FNABC, BRAF mutation was detected in 6 of 102 cases in cell paucity and in 11 of 74 cases in the atypia. Two cases were not detected in the atypia. The sensitivity and specificity of PCR-RFLP in FNABC were 60% and 97.4% respectively. Assessment of Formalin Fixed Paraffin Embedding (FFPE) block demonstrated similarly a 51.1% positive and 48.9% negative in PTC. Evaluation of BRAF mutation revealed high specificity and low sensitivity in using FNABC method. This study suggests that BRAF mutation analysis should be useful for the clinical diagnosis of PTC in FNABC with cytological findings suspicious for PTC.
참고문헌 (28)
- Adeniran AJ, "Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas", Am J Surg Pathol, 30, pp.216~222 (2006)
- Chung KW, "Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAFV600E mutation-prevalent area", Clin Endoclinol, 65, pp.660~666 (2006)
- Davies L, "Increasing incidence of thyroid cancer in the United States, 1973-2002", JAMA, 295, pp.2164~2167 (2006)
- Gharib H, "Fine-needle aspiration biopsy of the thyroid: an appraisal", Ann Intern Med, 118, pp.282~289 (1993)
- Jo YS, "Diagnostic value of pyrosequencing for the BRAFV600E mutation in ultrasound- guided fine-needle aspiration biopsy samples of thyroid incidentalomas", Clin Endoclinol, 70, pp.139~144 (2009)
- Jo YS, "Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer", J Clin Endocrinol Metab, 91, pp.3667~3670 (2006)
- Kelman AS, "Thyroid cytology and the risk of malignancy in thyroid nodules: importance of nuclear atypia in indeterminate specimens", Thyroid, 11, pp.271~277 (2001)
- 홍순원, "세포검사로 유두갑상샘암종이 의심되는 갑상샘 결절의 Galectin-3 발현과 BRAF 돌연변이 분석", Journal of Pathology and Translational Medicine, 44(2), pp.191~198 (2010), 대한병리학회
- 김경희, "Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population", Yonsei Medical Journal, 45(5), pp.818~821 (2004), 연세대학교의과대학
- Kim SK, "Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules", Diagn Mol Pathol, 17, pp.118~125 (2008)
- Lee JH, "Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a metaanalysis", Cancer, 110, pp.38~46 (2007)
- Lee JH, "BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas", Pathology, 38, pp.201~204 (2006)
- Leenhardt L, "Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee", Thyroid, 14, pp.1056~1060 (2004)
- Liu D, "Suppression of BRAF", MEK, Clin Cancer Res, pp.2007, 13[DOI]
- Marais R, "Control of the ERK MAP kinase cascade by Ras and Raf", Cancer Surv, 27, pp.101~125 (1996)
- Namba H, "Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers", J Clin Endocrinol Metab, 88, pp.4393~4397 (2003)
- Nikiforova MN, "Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis", Expert Rev Mol Diagn, 8, pp.83~95 (2008)
- Oertel YC, "Thyroid cytology and histology", Baillieres Best Pract Res Clin Endocrinol Metab, 14, pp.541~557 (2000)
- Prasad ML, "Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin- 19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors", Mod Pathol, 18, pp.48~57 (2005)
- Rapp UR, "Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus", Proc Natl Acad Sci USA, 80, pp.4218~4222 (1983)
- Rowe LR, "Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules", Cytojournal, 3, pp.10~ (2006)
- Saggiorato E, "Characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application", Endocr Relat Cancer, 12, pp.305~317 (2005)
- Santarpia L, "Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma", Hum Pathol, 40, pp.827~833 (2009)
- Sapio MR, "Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma", Endocr Relat Cancer, 14, pp.1089~1097 (2007)
- Sheu SY, "Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET", PTC rearrangements, 2007, pp.20, 779~787
- Wan PT, "Machanism of activation of the RAF-ERK signaling pathway by oncogenic mutation of B-RAF", Cell, 116, pp.855~867 (2004)
- Wellbrock C, "The RAF proteins take centre stage", Nat Rev Mol, 5, pp.875~885 (2004)
- Xing M, "BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications", Endocr Rev, 28, pp.742~762 (2007)